JohnSHromMD

Physician

Dr. Hrom is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Mississippi Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Mississippi School of MedicineClass of 2003

PubMed

3 citations
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Marek Trněný, Abraham Avigdor, Matthew S McKinney, Shankara Paneesha, Björn E Wahlin, John S Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Or...> ;Eclinicalmedicine. 2023 Sep 1
1 citations
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezo...
David Daniely, Eli Forouzan, Tanya M Spektor, Alexa Cohen, Jacob D Bitran, Gigi Chen, Mehdi M Moezi, Alberto Bessudo, John Hrom, Shahrooz Eshaghian, Regina A Swift, Be...> ;Experimental Hematology. 2022 Jul 1
153 citations
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Brendan Bulik-Sullivan, Jennifer Busby, Christine D. Palmer, Matthew J. Davis, Tyler Murphy, Andrew Clark, Michele Busby, Fujiko Duke, Aaron Yang, Lauren Young, Noelle...> ;Nature Biotechnology. 2019 Jan 1